Related Experiment Videos
Botulinum toxin type A therapy for hemifacial spasm.
J Costa1, C Espírito-Santo, A Borges
1Instituto de Farmacologia e Terapêutica Geral, Faculdade de Medicina Lisboa, Av. Prof. Egas Moniz, Lisboa, Portugal, 1649-028. joaoncosta@sapo.pt
The Cochrane Database of Systematic Reviews
|January 28, 2005
Summary
Botulinum toxin type A (BtA) effectively treats hemifacial spasm, offering a safe alternative to other treatments. While one study showed superiority over placebo, further research is needed on optimal application and long-term effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Hemifacial spasm involves involuntary unilateral facial muscle contractions.
- Often caused by vascular compression of the facial nerve.
- Can lead to significant cosmetic and functional impairment.
Purpose of the Study:
- To evaluate the efficacy and safety of Botulinum toxin type A (BtA) for treating hemifacial spasm.
Main Methods:
- Systematic search of multiple databases (Cochrane, MEDLINE, EMBASE) and contact with researchers.
- Included randomized controlled trials comparing BtA with placebo.
- Data extraction and quality assessment by two independent reviewers.
Main Results:
- One small randomized, placebo-controlled crossover trial with 11 participants was identified.
- BtA demonstrated superiority over placebo in reducing hemifacial spasm symptoms.
- Adverse effects were collected from trial data.
Conclusions:
- Findings support existing evidence from open-label studies indicating BtA's effectiveness and safety.
- Challenges exist in conducting large placebo-controlled trials due to expected high efficacy.
- Further research should focus on optimal BtA application, long-term outcomes, and comparison with microvascular decompression.